AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28678647
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide 5% gel, liquid cleanser, and moisturizer SPF 30
Trial: 28678771
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D status (25(OH)D <50 nmol/l)
Trial: 28678771
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D status (25(OH)D ≥75 nmol/l)
Trial: 28678771
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D status (25(OH)D 50-74.9 nmol/l)
Trial: 28679598
Drug: MP-Ld (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP-Ld (12.5 mg/kg)
Trial: 28679598
Drug: MP-Hd (17.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP-Hd (17.5 mg/kg)
Trial: 28679598
Drug: LD+DDCI (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD+DDCI (3.5 mg/kg)
Trial: 28679598
Drug: LD-DDCI (17.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD-DDCI (17.5 mg/kg)
Trial: 28680916
Drug: Lipoic acid
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoic acid (LA) 1,200 mg daily
Trial: 28681650
Drug: E6011 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 100 mg
Trial: 28681650
Drug: E6011 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6011 400 mg
Trial: 28683732
Drug: Common treatment
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common treatment regimens for AIS
Trial: 28683732
Drug: Different treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different treatment regimens for AIS
Trial: 28684537
Drug: Pomalidomide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide (4 mg by mouth on days 1 to 21), bortezomib (1.0 mg/m2 IV or subcutaneous), dexamethasone
Trial: 28685973
Drug: Exenatide BID
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide BID (10 μg)
Trial: 28686124
Drug: Convection-enhanced delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convection-enhanced delivery (CED) with a radiolabeled antibody
Trial: 28687231
Drug: Different controller
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different controller therapies
Trial: 28687349
Drug: Lung cancer
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung cancer screening and tobacco cessation program; details on dosage and duration not available.
Trial: 28687625
Drug: Ofatumumab (OFA)
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab (OFA) infusion at an accelerated regimen: 300 mg on week 1 day 1, 1,000 mg on week 1 day 3, 2,000 mg on week 2 day 1, followed by weekly infusions for 8 weeks and monthly for 4 months.
Trial: 28687627
Drug: Sorafenib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib and capecitabine combination therapy
Trial: 28688730
Drug: Medical Orders
RxNorm normalized name: Orderable Drug Form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Orders for Scope of Treatment (MOST) documentation
Trial: 28689278
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tHcy assessment and Ut-A Doppler
Trial: 28690586
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (radiotherapy and chemotherapy)
Trial: 28691931
Drug: Topical gentamicin
RxNorm normalized name: gentamicin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gentamicin (0.1% ointment applied 3 times daily for 2 weeks)
Trial: 28691931
Drug: Intradermal gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal gentamicin (8 mg solution injected daily for 2 days)
Trial: 28691931
Drug: Placebo (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (topical and intradermal)
Trial: 28692407
Drug: No formal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No formal treatment (Narcotics Anonymous/Alcoholics Anonymous or halfway house)
Trial: 28692407
Drug: No postdetoxification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postdetoxification treatment
Trial: 28692407
Drug: History of
RxNorm normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History of drug overdose
Trial: 28694343
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers non-withdrawal during acute heart failure
Trial: 28694343
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers non-withdrawal during acute heart failure (ADCHF only)
Trial: 28694343
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers non-withdrawal
Trial: 28694343
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers withdrawal
Trial: 28696231
Drug: Nafithromycin 800
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nafithromycin 800 mg once daily for 3 days
Trial: 28698106
Drug: Loss in
RxNorm normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loss in knee extensor strength in women concurrent with symptomatic progression
Trial: 28698106
Drug: Loss in
RxNorm normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loss in knee flexor strength in women concurrent with symptomatic progression
Trial: 28698106
Drug: Loss in
RxNorm normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loss in knee extensor and flexor strength concurrent with radiographic progression
Trial: 28698330
Drug: Biological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological therapy (specific biologic agent not mentioned)
Trial: 28699641
Drug: Nilotinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib (300 to 400 mg twice daily)
Trial: 28699641
Drug: Nilotinib dose
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib dose escalation for lack of efficacy
Trial: 28699641
Drug: Nilotinib dose
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib dose reduction due to adverse events
Trial: 28699641
Drug: Nilotinib re-escalation
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib re-escalation after dose reduction
Trial: 28700265
Drug: Quadrivalent influenza
RxNorm normalized name: influenza A virus (H1N1) antigen / influenza A virus (H3N2) antigen / influenza B virus antigen Injection [Fluzone Quadrivalent 2021-2022]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent influenza vaccine (IIV4)
Trial: 28700265
Drug: Trivalent influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent influenza vaccine (IIV3) containing B Victoria-lineage strain
Trial: 28700265
Drug: Trivalent influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent influenza vaccine (IIV3) containing B Yamagata-lineage strain
Trial: 28700272
Drug: MiniMed 640G
RxNorm normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MiniMed 640G insulin pump
Trial: 28701316
Drug: hs-cTnI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnI with delta hs-cTnI (0 and 3 h) >5 ng/L
Trial: 28701571
Drug: nab-Paclitaxel (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-Paclitaxel (150 mg/m2 weekly for four cycles)
Trial: 28702291
Drug: Neonatal pneumococcal
RxNorm normalized name: Foreskin fibroblast (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neonatal pneumococcal conjugate vaccine
Trial: 28702844
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ASA and LMWH
Trial: 28702844
Drug: Therapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic dose of LMWH
Trial: 28702844
Drug: ASA medication
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA medication
Trial: 28705182
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and paclitaxel with concurrent radiotherapy (41.4-45 and 50.4 Gy)
Trial: 28705184
Drug: POC 1-h
RxNorm normalized name: Bis(POC)PMPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POC 1-h 50 g GCT (≥7.2 mmol/L [129.6 mg/dL])
Trial: 28705532
Drug: Galantamine-memantine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine-memantine combination
Trial: 28706103
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D metabolites and associated hormones measurements in AKI patients
Trial: 28706103
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D metabolites and associated hormones measurements in non-AKI patients
Trial: 28706563
Drug: OFC (6/25-12/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OFC (6/25-12/50 mg/day olanzapine/fluoxetine)
Trial: 28707359
Drug: Pedometer tracking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pedometer tracking of daily steps
Trial: 28708962
Drug: Ad5-EBOV (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-EBOV (one shot intramuscular injection)
Trial: 28708962
Drug: Ad5-EBOV (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-EBOV (high-dose group)
Trial: 28709412
Drug: Propranolol 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 0.2% eye micro-drops treatment until retinal vascularization is completed, but for no longer than 90 days.
Trial: 28709439
Drug: Routine antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antibiotic management (RAM)
Trial: 28710110
Drug: Patient-tailored complementary/integrative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-tailored complementary/integrative medicine (CIM) programme, with adherence defined as attending ≥4 CIM treatments, with ≤30 days between each session.
Trial: 28710747
Drug: CART-HER2 cells
RxNorm normalized name: RHUMAB HER2
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CART-HER2 cells infused after conditioning treatment with nab-paclitaxel (100-200 mg/m2)
Trial: 28711173
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of RT-PCR and ddPCR
Trial: 28712533
Drug: 60Gy intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60Gy intensity modulated radiotherapy with concurrent weekly intravenous cisplatinum
Trial: 28713062
Drug: Second-generation colon
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation colon capsule endoscopy (CCE-2)
Trial: 28713365
Drug: Detection and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection and quantification of immune compounds in human milk
Trial: 28713581
Drug: Elevated protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated protein intake (EPI, 20% of daily calorie intake)
Trial: 28713581
Drug: Recommended protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended protein intake (RPI, 10% of daily calorie intake)
Trial: 28716801
Drug: ACR+ve diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACR+ve diabetes mellitus patients after 1-year treatment with renin-angiotensin-aldosterone blockade
Trial: 28716862
Drug: Autologous gene
RxNorm normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous gene therapy using a self-inactivating lentiviral vector (LV-w1.6 WASp) after reduced-intensity conditioning
Trial: 28717036
Drug: Health care
RxNorm normalized name: Health Care Lancing Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health care workers (HCWs) wearing gowns and gloves (G&G) during usual care activities.
Trial: 28717516
Drug: Intravenous Darbepoetin
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Darbepoetin (DA)
Trial: 28717516
Drug: Intravenous Epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Epoetin (EPO)
Trial: 28719652
Drug: HIVconsv vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIVconsv vaccine (plasmid DNA, simian adenovirus, poxvirus MVA)
Trial: 28719652
Drug: HIVconsv vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIVconsv vaccine
Trial: 28720129
Drug: RTW-focused approach
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTW-focused approach in therapy
Trial: 28720129
Drug: Baseline work
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline work ability and expectancy of future work ability, history of psychiatric treatment, focus on RTW in treatment
Trial: 28720129
Drug: Improvement in
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Improvement in expectations of future work ability at post-treatment
Trial: 28720549
Drug: HSV-1/ganciclovir treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSV-1/ganciclovir treatment.
Trial: 28721067
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg pasireotide long-acting release (LAR) i.m.
Trial: 28721067
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg pasireotide long-acting release (LAR) i.m.
Trial: 28724380
Drug: Access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access to and use of TVs, cell phones, tablets, and video games in the bedroom
Trial: 28724445
Drug: Combined plasmapheresis
RxNorm normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined plasmapheresis (PE) and allogeneic mesenchymal stem cells transplantation (MSCT) therapy
Trial: 28724646
Drug: Trimethylamine treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethylamine treatment, dosage and duration not specified
Trial: 28724795
Drug: ALX receptor
RxNorm normalized name: ALX-009
DrugBank: ALX-009 (DB17916)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALX receptor expression in BAL macrophages
Trial: 28725257
Drug: Breastfeeding relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breastfeeding relaxation therapy (daily audio recording during breastfeeding)
Trial: 28725594
Drug: Weekly infusions
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly infusions of ascorbic acid (AA); week 1: 5 g, week 2: 30 g, weeks 3-12: 60 g
Trial: 28725594
Drug: Weekly infusions
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly infusions of ascorbic acid (AA)
Trial: 28727583
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine and bupivacaine HCl mixture (266 mg liposomal bupivacaine and 125 mg 0.25% bupivacaine HCl with epinephrine 1:300,000)
Trial: 28730692
Drug: Cross-sex hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-sex hormone therapy (CSHT) for trans men
Trial: 28730692
Drug: Cross-sex hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-sex hormone therapy (CSHT) for trans women
Trial: 28733294
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (specific details not provided)
Trial: 28733943
Drug: OnabotulinumtoxinA injections
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA injections (70 to 150 U per session, targeted to pericranial myofascial sites)
Trial: 28733943
Drug: OnabotulinumtoxinA injections
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA injections
Trial: 28735291
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low coronary artery calcium score and low high-sensitivity cardiac troponin T
Trial: 28736443
Drug: CLOCK 3111C
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLOCK 3111C carriers (CC and TC)
Trial: 28736443
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss during treatment program
Trial: 28739783
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg, once daily)
Trial: 28740367
Drug: Comprehensive lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive lifestyle changes and/or metformin treatment
Trial: 28746812
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells (AD MSCs)
Trial: 28747274
Drug: On-demand PrEP
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand PrEP (tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg) taken before and after sexual intercourse
Trial: 28747857
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted cessation intervention (treatment arm) with nicotine patches for 8 weeks
Trial: 28747857
Drug: Standard cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cognitive behavioral therapy (comparison arm) with nicotine patches for 8 weeks
Trial: 28750271
Drug: LY2780301 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2780301 500 mg QD plus gemcitabine 750 mg/m²
Trial: 28750271
Drug: LY2780301 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2780301 400 mg QD plus gemcitabine 1000 mg/m²
Trial: 28750271
Drug: LY2780301 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2780301 500 mg QD plus gemcitabine 1000 mg/m²
Trial: 28750271
Drug: LY2780301 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2780301 400 mg QD plus gemcitabine 750 mg/m²
Trial: 28750429
Drug: Insulin-treated patients
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-treated patients with diabetes
Trial: 28750608
Drug: Anti-arrhythmic drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-arrhythmic drug therapy
Trial: 28750659
Drug: 8 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 cycles of modified FOLFIRINOX (oxaliplatin 85 mg/m2, details of other drugs not provided)
Trial: 28750659
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus hypofractionated radiation therapy
Trial: 28751088
Drug: Hypoalbuminemia group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoalbuminemia group (Hypo-AG, serum albumin <28 g/L)
Trial: 28751088
Drug: Marginal hypoalbuminemia
RxNorm normalized name: Culex marginalis
DrugBank: Culex pipiens (DB14165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marginal hypoalbuminemia group (Margin-AG, serum albumin 28-34.9 g/L)
Trial: 28751088
Drug: Normal albuminemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal albuminemia group (Normal-AG, serum albumin ≥35 g/L)
Trial: 28751247
Drug: Osimertinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80 or 160 mg daily)
Trial: 28752370
Drug: L-NMMA and
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA and diclofenac
Trial: 28752679
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of autologous stimulated bone marrow stem cells (BM-SC)